Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $58.00 → $45.00 | Outperform | Leerink Partners |
| 1/7/2022 | $76.00 → $70.00 | Outperform | SVB Leerink |
| 8/25/2021 | $74.00 → $76.00 | Outperform | SVB Leerink |
The Annual General Meeting of PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech Health" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below. Resolutions For % Against % Withheld Total votes cast 001. To approve the Company's Annual Report and Accounts for year ended 31 December 2024 161,252,066 99.97% 43,159 0.03% 43,897 161,295,225 002. To
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, PhD, JD, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30am EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastatin
Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression Detailed safety analysis underscores favorable tolerability profile for deupirfenidone PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage bio
Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously
SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously
SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously
6-K - PureTech Health plc (0001782999) (Filer)
20-F - PureTech Health plc (0001782999) (Filer)
6-K - PureTech Health plc (0001782999) (Filer)